Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogenic mutations inactivate parkin by distinct mechanisms.

Iris H Henn1, Johanna M Gostner, Peter Lackner

  • 1Department of Cellular Biochemistry, Max Planck Institute for Biochemistry, Martinsried, Germany.

Journal of Neurochemistry
|December 21, 2004
PubMed
Summary

Parkin mutations cause Parkinson's disease through distinct inactivation pathways. C-terminal deletions cause misfolding, while N-terminal mutations lead to proteasomal degradation of parkin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TRPV1 Agonist Capsaicin Enhances Oxidative-Stress Resistance and Regeneration in Dorsal Root Ganglia and Schwann Cells.

Cells·2026
Same author

Biomarkers and potential subtypes of acute mountain sickness: A state-of-the-science review.

Redox biology·2026
Same author

New approach methodologies (NAMs) to support regulatory assessment of developmental immunotoxicity - a new PARC project.

Frontiers in toxicology·2026
Same author

A Novel 3D Semi-Automated Full Quantification Technique for Detection of Intraneural Phospho-α-Synuclein in Skin Biopsies.

European journal of neurology·2026
Same author

Phosphoinositide kinase PIKfyve inhibitor apilimod blocks hepatitis E virus infection.

eGastroenterology·2026
Same author

A Validated Method for the Simultaneous Measurement of Tryptophan, Kynurenine, Phenylalanine, and Tyrosine by High-Performance Liquid Chromatography-Ultraviolet/Fluorescence Detection in Human Plasma and Serum.

ACS omega·2026

Area of Science:

  • Neuroscience
  • Genetics
  • Cell Biology

Background:

  • Loss of parkin function is a primary cause of autosomal recessive Parkinson's disease (ARPD).
  • The precise mechanisms underlying the inactivation of mutant parkin remain largely unknown.
  • Parkin is an E3 ubiquitin ligase crucial for protein quality control and mitochondrial homeostasis.

Purpose of the Study:

  • To characterize the distinct pathophysiological mechanisms leading to the inactivation of pathogenic C- and N-terminal parkin mutants.
  • To elucidate how different parkin mutations affect protein stability, localization, and degradation.
  • To investigate the origin and nature of a smaller parkin species found in human tissues.

Main Methods:

  • Characterization of pathogenic C- and N-terminal parkin mutants.

Related Experiment Videos

  • Analysis of parkin association with cellular membranes.
  • Assessment of protein misfolding, aggregation, and degradation pathways (e.g., proteasome).
  • Biochemical analysis of parkin species in human brain and cell extracts.

    • Main Results:

    • Deletion of the C terminus of parkin disrupted its membrane association, leading to rapid misfolding and aggregation.
    • Four N-terminal missense mutations within the ubiquitin-like domain (UBL) destabilized parkin, causing its rapid degradation by the proteasome.
    • Evidence was found for a 42 kDa parkin species, lacking the N-terminal UBL domain, originating from an internal start site.

    Conclusions:

    • Pathogenic parkin mutations inactivate the protein through distinct mechanisms involving misfolding/aggregation or proteasomal degradation.
    • The N-terminal UBL domain is critical for parkin stability, and its loss leads to rapid degradation.
    • Understanding these inactivation pathways is crucial for developing therapeutic strategies for ARPD.